WO1991000100A3 - Toxin uses - Google Patents

Toxin uses Download PDF

Info

Publication number
WO1991000100A3
WO1991000100A3 PCT/GB1990/000992 GB9000992W WO9100100A3 WO 1991000100 A3 WO1991000100 A3 WO 1991000100A3 GB 9000992 W GB9000992 W GB 9000992W WO 9100100 A3 WO9100100 A3 WO 9100100A3
Authority
WO
WIPO (PCT)
Prior art keywords
toxin
cell
combined
mitogenic
fermentations
Prior art date
Application number
PCT/GB1990/000992
Other languages
French (fr)
Other versions
WO1991000100A2 (en
Inventor
Neil Chanter
Alistair John Lax
Juan Enrique Rozengurt
Original Assignee
Animal Health Inst
Imp Cancer Res Tech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Animal Health Inst, Imp Cancer Res Tech filed Critical Animal Health Inst
Publication of WO1991000100A2 publication Critical patent/WO1991000100A2/en
Publication of WO1991000100A3 publication Critical patent/WO1991000100A3/en
Priority to GB9125997A priority Critical patent/GB2252105A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/285—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pasteurellaceae (F), e.g. Haemophilus influenza
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6829—Bacterial toxins, e.g. diphteria toxins or Pseudomonas exotoxin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

The toxin from Pasteurella multocida, which causes atrophic rhinitis in pigs, has been characterised and been shown to be highly mitogenic. It may be used to accelerate cell growth (in fermentations, in bone marrow to be returned to the patient, and in wounds). Mitogenic fragments of it may be combined with cell-targeting entities, and cell-binding portions of it may be combined with cytotoxic or other pharmacologically active agents. The gene for the toxin has been cloned and expressed in E. coli.
PCT/GB1990/000992 1989-06-29 1990-06-27 Toxin uses WO1991000100A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
GB9125997A GB2252105A (en) 1989-06-29 1991-12-06 Toxin uses

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB898914984A GB8914984D0 (en) 1989-06-29 1989-06-29 Nucleotide sequences
GB8914984.3 1989-06-29

Publications (2)

Publication Number Publication Date
WO1991000100A2 WO1991000100A2 (en) 1991-01-10
WO1991000100A3 true WO1991000100A3 (en) 1991-04-04

Family

ID=10659288

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1990/000992 WO1991000100A2 (en) 1989-06-29 1990-06-27 Toxin uses

Country Status (4)

Country Link
EP (1) EP0482018A1 (en)
JP (1) JPH05500657A (en)
GB (2) GB8914984D0 (en)
WO (1) WO1991000100A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK120792D0 (en) * 1992-09-30 1992-09-30 Bioteknologisk Inst PROTEIN
GB9524807D0 (en) * 1995-12-05 1996-02-07 Smithkline Beecham Plc Novel compounds
DE102004035606A1 (en) * 2004-07-22 2006-03-30 Biotecon Therapeutics Gmbh Carrier for drugs for obtaining oral bioavailability

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Proc. Natl. Acad. Sci. USA, vol. 87, January 1990, E. Rozengurt et al.: "Pasteurella multocida toxin: Potent mitogen for cultured fibroblasts", pages 123-127 *

Also Published As

Publication number Publication date
WO1991000100A2 (en) 1991-01-10
GB9125997D0 (en) 1992-05-20
GB2252105A (en) 1992-07-29
GB8914984D0 (en) 1989-08-23
EP0482018A1 (en) 1992-04-29
JPH05500657A (en) 1993-02-12

Similar Documents

Publication Publication Date Title
IE852593L (en) Compositions containing anthracycline glycosides
AU2275397A (en) Troponin subunits and fragments useful as angiogenesis inhibitors
AU6373094A (en) Enzyme-containing pharmaceutical or cosmetic composition, process for preparing the same and its use
ZA949309B (en) Composition for the production of therapeutic products in vivo
CA2054752A1 (en) Pharmaceutical composition comprising loratadine, ibuprofen and pseudoephedrine
MX9502034A (en) Stable, lyophilized formulation, comprising a protein and dispensing equipment.
AU2982889A (en) Novel dosage form of fenofibrate
AU6666096A (en) Pharmaceutical composition containing il-10
UA56989C2 (en) PHYSIOLOGICALLY ACTIVE PEG-CONJUGATE OF a-INTERFERON, A METHOD FOR PREPARING THE SAME, A PHARMACEUTICAL COMPOSITION BASED THEREON AND A METHOD FOR TREATMENT OR PROPHYLAXIS OF IMMUNOMODULAR DISEASES
MY130157A (en) Method of use for inhibiting bone loss and lowering serum cholesterol
CA2204277A1 (en) Combined meningitis vaccine
CA2254079A1 (en) Androstene derivatives
MX9704030A (en) 2-heterocyclyloxy and thiomethyl-1,2,5-thiadiazolidin-3-one 1,1-dioxides and compositions and method of use thereof.
EP0797999A3 (en) Formulations of obesity protein
CA2186269A1 (en) Wound healing
IE891032L (en) Pharmaceutical compositions of piroxicam in aqueous solutions and process for their preparation
NZ500589A (en) Leptin (ob protein) and active fractions and fragments thereof as inhibitors of tumor cell proliferation
CA2234263A1 (en) Pharmaceutical composition for treating papillomavirus tumours and infection
WO1994008613A3 (en) Use of parathormone, of its biologically active fragments and of related peptides for treatment of pregnancy
AU5015396A (en) Thiazole and thiadiazole derivatives, their preparation and pharmaceutical compositions useful in the treatment of throm bocytopenia
AU574024B2 (en) Polycaprolactone matrix for oral drug administration
CA2268305A1 (en) Use of an h+, k+-atpase inhibitor in the treatment of nasal polyps
AU2670495A (en) Ifn-beta liquid formulations
DE69120287D1 (en) Aminosulfonylharnstoff-acat-inhibitoren
AU6245390A (en) Recombinant aprotinin variants - genetically engineered process for the microbial preparation of homogeneously processed aprotinin variants and the therapeutic use thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): GB JP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB IT LU NL SE

AK Designated states

Kind code of ref document: A3

Designated state(s): GB JP US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB IT LU NL SE

WWE Wipo information: entry into national phase

Ref document number: 1990909525

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1990909525

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1990909525

Country of ref document: EP